Mounjaro Shortage: GLP-1 Alternatives & Clinical Context

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mounjaro (tirzepatide) supply continues to experience intermittent constraints in 2024-2025, affecting patient access and treatment timing. Understanding the clinical context and your individual GLP-1 and GIPR pathway genetics may support more personalized alternative discussions with your provider.

For patients navigating Mounjaro shortage impacts, precision wellness data—including genetic predispositions and biomarker context—can help clarify which GLP-1 receptor-active approaches may align with your metabolic profile. This matters because shortage-driven treatment shifts should account for individual variation, not just availability.

Why Mounjaro Supply Remains Constrained and What This Means for Patients

Mounjaro demand has exceeded manufacturing capacity since its 2022 FDA approval for type 2 diabetes, driven by off-label GLP-1 interest. Eli Lilly expanded production, but periodic allocation and pharmacy-level shortages persist, particularly at lower dose strengths.

Shortages create delays in treatment initiation and dose escalation. Providers must weigh clinical urgency against wait times. Understanding the gap between Mounjaro demand and your treatment timeline helps inform whether alternative GLP-1 or dual-agonist pathways warrant consideration now.

GLP-1 Receptor and GIPR Pathway Genetics: Context for Shortage-Related Treatment Changes

Mounjaro activates both GLP-1 and GIPR receptors. Individual variation in GLP1R (rs6923761) and GIPR (rs1800437) gene variants may influence response magnitude and tolerability patterns. Genetic predisposition data can contextualize why some patients thrive on specific dual-agonist formulations.

If a Mounjaro shortage forces a treatment pivot, knowing your GLP1R and GIPR predisposition pattern may help your provider select a compounded alternative that aligns with your genetic pathway landscape. This isn't prediction of exact response—it's context for a more informed decision.

GLP-1 Pathway Factor	Clinical Relevance in Shortage Scenarios
GLP1R rs6923761 variant	May influence GLP-1 receptor sensitivity and dose response trajectory
GIPR rs1800437 variant	May relate to appetite-suppression efficacy and metabolic effect magnitude
FTO rs9939609 status	May contextualize baseline metabolic risk and weight-loss plateau likelihood
MC4R rs17782313 status	May inform predisposition to monogenic obesity-related mechanisms

Clinical Alternatives During Mounjaro Shortage: Compounded and Branded Options

Compounded tirzepatide from licensed 503A pharmacies offers chemically identical tirzepatide formulations at lower cost ($249/mo) with shorter wait times than branded Mounjaro. No FDA approval claim is made for compounded versions, but clinical bioequivalence to the branded product has been established in compounding literature.

Semaglutide (GLP-1 only, vs. tirzepatide's dual action) represents a single-pathway alternative. Compounded semaglutide injection ($149/mo) and oral semaglutide ($209+/mo) provide access without Mounjaro wait constraints. Microdose GLP-1 protocols ($129/mo) offer lower-cost entry points for dose-titration strategies.

Who Should Pivot from Mounjaro and What to Discuss with Your Provider

Patients with urgent metabolic goals, those experiencing significant Mounjaro delays, or individuals with contraindications (pancreatitis history, MTC familial syndrome, severe GI disease) should have alternative conversations with their provider now. Genetic predisposition data can clarify whether a single-pathway (semaglutide) or dual-pathway (tirzepatide) formulation better matches your biology.

Before switching, discuss: your GLP-1 pathway genetics if available, prior GLP-1 tolerability, baseline BMI and metabolic comorbidities, and treatment timeline urgency. Your provider can then evaluate whether a compounded alternative, dose escalation schedule, or combination approach aligns with clinical evidence and your individual predisposition profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in GLP1R, GIPR, FTO, and MC4R gene variants. This data may help provide context for why certain GLP-1 or dual-agonist pathways could align better with your metabolic architecture—especially valuable when Mounjaro shortage forces a treatment reassessment.

Genetic predisposition is not destiny or exact-response prediction. Instead, it illuminates your individual peptide-pathway landscape: which receptors may respond more robustly, whether single-agonist (semaglutide) or dual-agonist (tirzepatide) architecture fits your genetic profile, and what baseline expectations might apply. This should be interpreted with a qualified healthcare provider.

During a Mounjaro shortage-driven pivot, having your genetic context in hand accelerates provider conversations about compounded semaglutide, compounded tirzepatide, or other GLP-1 alternatives. Rather than trial-and-error switching, a precision-informed approach helps ensure your next treatment aligns with both clinical need and your individual GLP-1 and GIPR predisposition patterns.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is the Mounjaro shortage expected to end soon?

Eli Lilly has expanded production capacity, but periodic allocation constraints persist. Check with your pharmacy and provider for current local availability before assuming longer wait times will resolve immediately.

Are compounded tirzepatide and branded Mounjaro chemically the same?

Yes, compounded tirzepatide from licensed 503A pharmacies contains identical tirzepatide. However, compounded versions carry no FDA approval claim; efficacy relies on compounding quality standards and individual provider judgment.

How much do compounded GLP-1 and tirzepatide alternatives cost at PlexusDx?

Compounded semaglutide injection: $149/mo. Oral semaglutide: $209+/mo. Compounded tirzepatide: $249/mo. Microdose GLP-1 protocol: $129/mo. Pricing varies by formulation and supply.

What side effects should I expect when switching from Mounjaro to an alternative?

GLP-1 and dual-agonist side effects overlap: nausea, vomiting, constipation, appetite changes. Tolerability often depends on dose escalation speed and individual GLP1R/GIPR genetic predisposition. Discuss expected timeline and symptom management with your provider.

How does the Precision Peptide Genetic Test help during a Mounjaro shortage?

The test reveals GLP1R, GIPR, FTO, and MC4R predispositions, helping your provider select compounded semaglutide or tirzepatide alternatives that better align with your genetic pathway profile—accelerating informed decision-making when shortage forces a switch.

Mounjaro Shortage: Clinical Evidence and Alternative Options for GLP-1 Therapy